Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: HLS Therapeutics Inc.

Market Cap 97.67M 84.14M 77.5M 72.61M 136M 9.29B 138M 917M 357M 4.52B 366M 359M 15.62B P/E Ratio 2026 *
-15.6x
P/E Ratio 2027 * -104x
Enterprise Value 97.67M 84.14M 77.5M 72.61M 136M 9.29B 138M 917M 357M 4.52B 366M 359M 15.62B EV / Sales 2026 *
1.68x
EV / Sales 2027 * 1.52x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day-3.37%
Current month-3.37%
1 month-7.95%
3 months-6.31%
6 months-7.89%
Current year-8.16%
1 month 3.15
Extreme 3.15
3.36
Current year 3
Extreme 3
3.44
1 year 3
Extreme 3
4.02
3 years 2.22
Extreme 2.22
4.95
5 years 2.22
Extreme 2.22
16.44
10 years 0
Extreme 0
19.1
Manager TitleAgeSince
Chief Executive Officer 58 2023-04-30
Director of Finance/CFO 61 2024-01-25
Chief Tech/Sci/R&D Officer 61 2014-05-31
Director TitleAgeSince
Chairman 48 2023-06-21
Director/Board Member 61 2023-06-21
Director/Board Member 58 2023-04-30
Change 5-day change 1-year change 3-year change Capi.($)
-3.37%0.00% - - 97.67M
-0.40%+1.08%+7.67%+97.49% 91.79B
+1.22%+8.82%+38.68%+154.32% 52.43B
-1.86%-9.59%-18.77%+214.29% 21.42B
+0.62%+0.49%-10.95%-25.32% 8.13B
-0.07%+2.43%-34.66%-28.05% 7.54B
+1.19%-1.22%-11.46%-36.80% 6.77B
-2.80%-2.46%+11.48%+21.79% 6.49B
+0.30%+1.01%-0.93%+17.66% 5.32B
+1.27%-3.62%-11.95%-14.53% 3.53B
Average -0.39%+0.94%-3.43%+44.54% 22.6B
Weighted average by Cap. -0.06%+3.45%+9.49%+103.96%

Financials

2026 *2027 *
Net sales 58.03M 49.99M 46.05M 43.14M 81.01M 5.52B 82M 545M 212M 2.68B 218M 213M 9.28B 64.31M 55.41M 51.04M 47.81M 89.78M 6.12B 90.88M 604M 235M 2.97B 241M 236M 10.28B
Net income -6.26M -5.4M -4.97M -4.66M -8.75M -596M -8.85M -58.85M -22.88M -290M -23.51M -23.01M -1B -1.05M -905K -833K -781K -1.47M -99.86M -1.48M -9.86M -3.83M -48.56M -3.94M -3.86M -168M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.123USD
Average target price
5.179USD
Spread / Average Target
+65.84%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!